Tumour hypoxia
dc.contributor.author | West, Catharine ML | |
dc.contributor.author | Slevin, F | |
dc.date.accessioned | 2019-09-11T09:09:19Z | |
dc.date.available | 2019-09-11T09:09:19Z | |
dc.date.issued | 2019 | en |
dc.identifier.citation | West CM, Slevin F. Tumour hypoxia. Clin Oncol. 2019;31(9):595-9. | en |
dc.identifier.pmid | 31301956 | en |
dc.identifier.doi | 10.1016/j.clon.2019.06.008 | en |
dc.identifier.uri | http://hdl.handle.net/10541/622038 | |
dc.description.abstract | Highlights •Oxygen fixes DNA damage by free radicals and cells are 2–3 times more radioresistant to sparsely ionising radiation when irradiated in the absence of oxygen. •OER, the ratio of radiation dose in hypoxia divided by radiation dose in air to produce the same biological effect, decreases with increasing LET. •Reoxygenation occurs during a course of fractionated radiotherapy making tumours cells more sensitive to radiation. •All solid tumour have some level of hypoxia that promotes angiogenesis and metastasis – it is associated with an aggressive phenotype. •High levels of tumour hypoxia are associated with a poor prognosis, hypoxia modification strategies are effective and patients with the most hypoxic tumours benefit most from hypoxia modifying treatments. | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1016/j.clon.2019.06.008 | en |
dc.title | Tumour hypoxia | en |
dc.type | Article | en |
dc.contributor.department | University of Manchester, Manchester Academic Health Science Centre, Department 58, Christie Hospital, Manchester M20 4BX, UK | en |
dc.identifier.journal | Clinical Oncology | en |
dc.description.note | en] |